Coya Therapeutics, Inc. Operating Cash Flow
Coya Therapeutics, Inc. (COYA) reported Operating Cash Flow of -$13.58 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-11
- Coya Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$7.38M.
- Coya Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$6.21M.
- Coya Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$1.01M.
- Coya Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$1.13M.
- Coya Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$10.74M.
- Coya Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$10.29M.
- Coya Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$11.19M.
- Coya Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$7.24M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$7.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$13.58M 10-Q · filed 2026-08-11 | -$14.59M derived: sum of 3 quarters · filed 2026-08-11 | -$15.72M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$6.21M 10-Q · filed 2026-05-12 | -$7.22M derived: sum of 2 quarters · filed 2026-05-12 | -$8.35M derived: sum of 3 quarters · filed 2026-05-12 | -$14.12M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$1.01M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$2.14M derived: sum of 2 quarters · filed 2026-03-16 | -$7.91M derived: sum of 3 quarters · filed 2026-08-11 | -$10.74M 10-K · filed 2026-03-16 |
| 2025-09-30 | -$1.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$6.90M derived: sum of 2 quarters · filed 2026-08-11 | -$9.73M 10-Q · filed 2025-11-12 | -$12.14M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$5.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$8.60M 10-Q · filed 2026-08-11 | -$11.01M derived: sum of 3 quarters · filed 2026-08-11 | -$16.47M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$2.83M 10-Q · filed 2026-05-12 | -$5.24M derived: sum of 2 quarters · filed 2026-05-12 | -$10.70M derived: sum of 3 quarters · filed 2026-05-12 | -$15.26M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$2.41M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$7.87M derived: sum of 2 quarters · filed 2026-03-16 | -$12.43M derived: sum of 3 quarters · filed 2026-03-16 | -$10.29M 10-K · filed 2026-03-16 |
| 2024-09-30 | -$5.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$10.02M derived: sum of 2 quarters · filed 2025-11-12 | -$7.88M 10-Q · filed 2025-11-12 | -$10.12M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$4.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$2.42M 10-Q · filed 2025-08-12 | -$4.66M derived: sum of 3 quarters · filed 2025-08-12 | -$6.87M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $2.15M 10-Q · filed 2025-05-13 | -$95.21K derived: sum of 2 quarters · filed 2025-05-13 | -$2.31M derived: sum of 3 quarters · filed 2025-05-13 | -$5.18M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$2.24M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | -$4.46M derived: sum of 2 quarters · filed 2025-03-18 | -$7.33M derived: sum of 3 quarters · filed 2025-03-18 | -$11.19M 10-K · filed 2025-03-18 |
| 2023-09-30 | -$2.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$5.08M derived: sum of 2 quarters · filed 2024-11-06 | -$8.95M 10-Q · filed 2024-11-06 | -$11.17M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | -$2.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$6.73M 10-Q · filed 2024-08-12 | -$8.95M derived: sum of 3 quarters · filed 2024-08-12 | -$10.55M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | -$3.86M 10-Q · filed 2024-05-09 | -$6.09M derived: sum of 2 quarters · filed 2024-05-09 | -$7.68M derived: sum of 3 quarters · filed 2024-05-09 | -$9.12M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$2.22M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | -$3.81M derived: sum of 2 quarters · filed 2024-03-19 | -$5.25M derived: sum of 3 quarters · filed 2024-03-19 | -$7.24M 10-K · filed 2024-03-19 |
| 2022-09-30 | -$1.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$3.03M derived: sum of 2 quarters · filed 2023-11-08 | -$5.02M 10-Q · filed 2023-11-08 | |
| 2022-06-30 | -$1.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$3.42M 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | -$1.98M 10-Q · filed 2023-05-10 | |||
| 2021-12-31 | -$3.90M 10-K · filed 2023-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |